Trial Profile
Phase II, open-label study of erlotinib (Tarceva) treatment In patients with locally advanced or metastatic non-small-cell lung cancer who present activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TRIGGER
- Sponsors Roche
- 28 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 02 Jul 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Jun 2015 Results assessing EGFR mutations in plasma presented at the 51st Annual Meeting of the American Society of Clinical Oncology.